Travoprost with sofZia&amp;reg; preservative system lowered intraocular pressure of Japanese normal tension glaucoma with minimal side effects

Mizoue, Shiro; Nakano, Tadashi; Fuse, Nobuo; Iwase, Aiko; Matsumoto, Shun; Yoshikawa, Keiji

doi:10.2147/opth.s57640

Cited by 14 publications

(8 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…14 Among the prostaglandin analog eye drops (bimatoprost, latanoprost, travoprost, and tafluprost), bimatoprost showed significantly strong IOP-lowering effects (Table 2). [15][16][17][18][19][20] Similar values of IOP reduction (12.0 ± 12.8%) were observed in the present study. Omidenepag isopropyl has been considered to have strong IOP lowering effects similar to prostaglandin analog eye drops in NTG patients.…”

Section: Discussionsupporting

confidence: 90%

<p>Short-Term Efficacy and Safety of Omidenepag Isopropyl in Patients with Normal-Tension Glaucoma</p>

Inoue¹,

Inoue²,

Kunimatsu-Sanuki³

et al. 2020

OPTH

View full text Add to dashboard Cite

To retrospectively evaluate the short-term efficacy of omidenepag isopropyl (EYBELIS 0.002%) by assessing its intraocular pressure (IOP)-lowering capability and safety in patients with normal-tension glaucoma (NTG). Patients and Methods: Fifty-four NTG patients (54 eyes) who were newly administrated with omidenepag isopropyl were enrolled in the study. The subjects comprised 22 men and 32 women, and the mean age of the subjects was 55.0 ± 14.1 years. The mean deviation value using the Humphrey visual field test program (30-2 SITA Standard) was −5.03 ± 3.38 dB. The following data were retrieved from the medical records and used for retrospective analyses: IOP at baseline 1-2 months and 3-4 months after administration. The frequency of non-responder patients who had less than 10% IOP reduction was evaluated. Patients were observed for adverse reactions and dropouts at each time point. Results: IOP at baseline, after 1-2 months and after 3-4 months was 15.7 ± 2.6 mmHg, 13.5 ± 2.3 mmHg, and 13.6 ± 2.4 mmHg, respectively. There was a significant decrease in IOP after administration (p<0.0001). Eleven patients (22.4%) were non-responders. Adverse reactions occurred in 4 patients (7.4%), including conjunctival hyperemia in 3 patients (after 1 week, 2 weeks, and 1 month, respectively) and eye pain in 1 patient (after 1 month). Five patients (9.3%) dropped out of the study because of an adverse reaction in 3 patients, insufficient IOP reduction in 1 patient, and discontinuation of follow-up of 1 patient at our institution. Conclusion: After administration of omidenepag isopropyl, IOP in patients with NTG was significantly decreased. However, adverse reactions occurred in 7.4% of patients.

show abstract

Section: Discussionsupporting

confidence: 90%

<p>Short-Term Efficacy and Safety of Omidenepag Isopropyl in Patients with Normal-Tension Glaucoma</p>

Inoue¹,

Inoue²,

Kunimatsu-Sanuki³

et al. 2020

OPTH

View full text Add to dashboard Cite

show abstract

“…Additional studies in NTG patients have shown a 20% reduction in diurnal IOP after timolol administered twice daily for 3 weeks [ 47 ], a 16% reduction in 24-h IOP after bimatoprost administered QD for 8 weeks [ 54 ], and a 24% reduction in IOP (mean of two daytime measurements) after bimatoprost administration QD for 2 weeks [ 55 ]. Studies with travoprost QD in NTG patients have shown an 11% reduction in mean IOP over 24 h after 4 weeks [ 56 ] and a 19.4% decrease in mean IOP measured within 2 h after drug administration in the evening after 12 weeks of treatment [ 57 ].…”

Section: Discussionmentioning

confidence: 99%

Evaluation of the Effect of Latanoprostene Bunod Ophthalmic Solution, 0.024% in Lowering Intraocular Pressure over 24 h in Healthy Japanese Subjects

Araie

Sforzolini²,

Vittitow³

et al. 2015

Adv Ther

View full text Add to dashboard Cite

IntroductionLatanoprostene bunod is a novel nitric oxide (NO)-donating prostaglandin F2α receptor agonist in clinical development for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. We evaluated the effect of latanoprostene bunod 0.024% instilled once daily (QD) on lowering IOP over a 24-h period in healthy Japanese subjects following 14 days of treatment.MethodsThis was a single-arm, single-center, open-label clinical study of 24 healthy Japanese male volunteers. A baseline IOP profile was established in both eyes in the sitting position at 8 PM, 10 PM, 12 AM, 2 AM, 4 AM, 8 AM, 10 AM, 12 PM, and 4 PM using a Goldmann applanation tonometer. Subjects subsequently instilled latanoprostene bunod 0.024% QD at 8 PM for 14 days in both eyes. The absolute and change from baseline in sitting IOP was assessed on day 14.ResultsThe mean (SD) age of the subjects was 26.8 (6.3) years, and mean (SD) baseline IOP was 13.6 (1.3) mmHg in the study eye. Latanoprostene bunod 0.024% instilled QD for 14 days reduced IOP at all the evaluated time points (P < 0.001) with a mean (SD) 24-h reduction of 3.6 (0.8) mmHg or 27% from the baseline in the study eye. Peak and trough IOP lowering occurred at 8 AM and 8 PM (12 and 24 h following instillation) with a mean reduction of 4.2 (1.8) mmHg, or 30%, and 2.8 (2.2) mmHg, or 20%, respectively. Punctate keratitis and ocular hyperemia, both mild in severity, were the most common adverse events.ConclusionLatanoprostene bunod ophthalmic solution 0.024%, dosed QD for 14 days, significantly lowered mean IOP in healthy Japanese subjects during the entire 24-h period. Studies of latanoprostene bunod in patients diagnosed with normal tension glaucoma are warranted.Trial RegistrationClinicaltrials.gov identifier NCT01895985.FundingBausch & Lomb, Inc.Electronic supplementary materialThe online version of this article (doi:10.1007/s12325-015-0260-y) contains supplementary material, which is available to authorized users.

show abstract

“…In Category 1, there were three articles for latanoprost, 15 – 17 two articles for travoprost, 18 , 19 one article for bimatoprost, 20 five articles for tafluprost 21 – 25 ( Table 1 ), and 0 articles for unoprostone. In Category 2, the number of articles for each PGA was as follows: 14 for latanoprost, 15 , 16 , 26 – 37 seven for travoprost, 18 , 19 , 26 , 38 – 41 three for bimatoprost, 20 , 26 , 40 seven for tafluprost, 21 – 23 , 25 , 26 , 39 , 40 and 0 articles for unoprostone ( Table 2 ).…”

Section: Resultsmentioning

confidence: 99%

Ocular hypotensive effects of prostaglandin analogs in Japanese patients with normal-tension glaucoma: a literature review

Takagi

Santo

Hashimoto

et al. 2018

OPTH

View full text Add to dashboard Cite

PurposeThis paper aimed to evaluate the intraocular pressure (IOP)-lowering effects of prostaglandin analogs (PGAs) in Japanese patients with normal-tension glaucoma (NTG) by reviewing the current literature.MethodsIn February 2018, database searches were performed in PubMed, Embase, ProQuest, and the Japanese databases JAPICDOC and JMEDPlus. Studies were sorted into two categories: Category 1 consisted of studies of patients with NTG who reported reduced IOP values and Category 2 consisted of studies of patients with NTG who had IOP values at predosing and a final evaluation point. Search terms included ([unoprostone or latanoprost or travoprost or bimatoprost or tafluprost] and [glaucoma] and [Japan or Japanese]). The weighted ocular hypotensive efficacy was calculated. A scatter plot analysis was performed and a regression equation was calculated for each medication. The fitting of each regression equation was evaluated by the least squares method.ResultsEleven articles were eligible for Category 1 and 25 articles for Category 2. In the rank order of IOP-lowering efficacy of PGAs, bimatoprost was the strongest and latanoprost the weakest. Travoprost and tafluprost had almost the same level of ocular hypotensive effect, and both were stronger than latanoprost. The scatter plot analysis showed that all PGAs reduced IOP by 15%–20%. At higher IOP (17–18 mmHg), the ocular hypotensive effect was almost the same with latanoprost, travoprost, and tafluprost. In contrast, at lower IOP (12–15 mmHg), the IOP reduction with latanoprost was weaker than with travoprost or tafluprost.ConclusionThis literature review of the ocular hypotensive effects of PGAs in Japanese patients with NTG highlighted that PGAs had different ocular hypotensive effects. Ophthalmologists should understand the IOP-lowering profiles of various PGAs and apply them to patients with NTG on a case-by-case basis.Trial registrationUMIN Clinical Trials Registry UMIN000032344.

show abstract

Travoprost with sofZia® preservative system lowered intraocular pressure of Japanese normal tension glaucoma with minimal side effects

Cited by 14 publications

References 23 publications

<p>Short-Term Efficacy and Safety of Omidenepag Isopropyl in Patients with Normal-Tension Glaucoma</p>

<p>Short-Term Efficacy and Safety of Omidenepag Isopropyl in Patients with Normal-Tension Glaucoma</p>

Evaluation of the Effect of Latanoprostene Bunod Ophthalmic Solution, 0.024% in Lowering Intraocular Pressure over 24 h in Healthy Japanese Subjects

Ocular hypotensive effects of prostaglandin analogs in Japanese patients with normal-tension glaucoma: a literature review

Contact Info

Product

Resources

About